O

Omeros Corp

D
OMER
USD
-0.04
(-0.8801%)
Market Closed
7,707.00
Volume
-1.76
EPS
-
Div Yield
-1.356928
P/E
261,050,599.80
Market Cap
Today
2.7366%
1 Week
11.510%
1 Month
17.013%
6 Months
23.594%
12 Months
217.254%
Year To Date
37.979%
All Time
0%

Title:
Omeros Corp

Sector:
Healthcare
Industry:
Biotechnology
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
Do you need help or have a question?